Hyperphagia in Prader-Willi Syndrome

3
Pipeline Programs
2
Companies
3
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
2
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Acadia Pharmaceuticals
2 programs
2
CarbetocinPhase 31 trial
CarbetocinPhase 31 trial
Active Trials
NCT06420297Enrolling By Invitation160Est. Jun 2029
NCT06173531Active Not Recruiting170Est. Nov 2025
Ferring Pharmaceuticals
Ferring PharmaceuticalsArgentina - Buenos Aires
1 program
1
FE 992097Phase 21 trial
Active Trials
NCT01968187Completed38Est. Jul 2014

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
Acadia PharmaceuticalsCarbetocin
Acadia PharmaceuticalsCarbetocin
Ferring PharmaceuticalsFE 992097

Clinical Trials (3)

Total enrollment: 368 patients across 3 trials

NCT06420297Acadia PharmaceuticalsCarbetocin

OLE Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome

Start: Mar 2024Est. completion: Jun 2029160 patients
Phase 3Enrolling By Invitation
NCT06173531Acadia PharmaceuticalsCarbetocin

Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome

Start: Nov 2023Est. completion: Nov 2025170 patients
Phase 3Active Not Recruiting
NCT01968187Ferring PharmaceuticalsFE 992097

Treatment of Hyperphagia Behavioral Symptoms in Children and Adults Diagnosed With Prader-Willi Syndrome

Start: Jan 2014Est. completion: Jul 201438 patients
Phase 2Completed

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs — potential near-term approvals
2 companies competing in this space